{"id":"low-dose-losartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction and aldosterone release. At low doses, it provides cardiovascular protection with potentially improved tolerability compared to standard doses, particularly in heart failure and hypertension management.","oneSentence":"Low-dose losartan blocks angiotensin II type 1 receptors to reduce blood pressure and improve cardiovascular outcomes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:26.047Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT02235909","phase":"PHASE3","title":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2015-03-30","conditions":"Hypertension","enrollment":377},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02676466","phase":"PHASE2","title":"The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-04-26","conditions":"Inflammation","enrollment":289},{"nctId":"NCT05064904","phase":"NA","title":"Multidiscipline Care for Acute Kidney Disease (AKD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-02-15","conditions":"Acute Kidney Injury","enrollment":300},{"nctId":"NCT03897868","phase":"PHASE2","title":"A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-03-21","conditions":"Hypertension","enrollment":248},{"nctId":"NCT04191681","phase":"PHASE4","title":"Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-11-08","conditions":"Stage D Heart Failure","enrollment":50},{"nctId":"NCT04428268","phase":"PHASE2","title":"Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia","status":"WITHDRAWN","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2020-03-10","conditions":"COVID-19 Pneumonia","enrollment":""},{"nctId":"NCT04349410","phase":"PHASE2, PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":"CoVid 19 Positive","enrollment":1800},{"nctId":"NCT02744456","phase":"EARLY_PHASE1","title":"N-of-1 Trials for Blood Pressure Medications in Adults","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-08-01","conditions":"Hypertension, High Blood Pressure","enrollment":10},{"nctId":"NCT02238457","phase":"PHASE4","title":"Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure Patients","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT01187862","phase":"PHASE1","title":"Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2010-07","conditions":"Cytochrome, Pharmacokinetics","enrollment":16},{"nctId":"NCT02269176","phase":"PHASE3","title":"Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-07","conditions":"Hypertension","enrollment":330},{"nctId":"NCT02200653","phase":"PHASE4","title":"A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-05","conditions":"Hypertension","enrollment":387},{"nctId":"NCT02200640","phase":"PHASE4","title":"A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-03","conditions":"Hypertension","enrollment":333},{"nctId":"NCT01087749","phase":"PHASE1","title":"Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-03","conditions":"Kidney Disease","enrollment":24},{"nctId":"NCT00907374","phase":"NA","title":"Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria","status":"COMPLETED","sponsor":"Charles Drew University of Medicine and Science","startDate":"2005-07","conditions":"Microalbuminuria","enrollment":46},{"nctId":"NCT01197001","phase":"PHASE1","title":"A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2010-08","conditions":"Healthy","enrollment":72},{"nctId":"NCT01115426","phase":"PHASE4","title":"Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis","status":"COMPLETED","sponsor":"University Magna Graecia","startDate":"1997-01","conditions":"IGA Glomerulonephritis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["losartan (Cozaar)"],"phase":"marketed","status":"active","brandName":"Low dose losartan","genericName":"Low dose losartan","companyName":"Baker Heart and Diabetes Institute","companyId":"baker-heart-and-diabetes-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose losartan blocks angiotensin II type 1 receptors to reduce blood pressure and improve cardiovascular outcomes. Used for Hypertension, Heart failure, Diabetic nephropathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}